GI Innovation said it has signed a memorandum of understanding (MOU) with i-Divine, a local company specializing in AI-based performance prediction solutions, to enhance clinical development strategies for its new drug pipelines through artificial intelligence (AI) collaboration.

Through this partnership, the two companies will focus on optimizing clinical development strategies for GI Innovation’s key cancer immunotherapy pipelines, GI-102 and GI-108, using i-Divine’s advanced AI technology.

i-Divine boasts a proprietary AI model that analyzes over 1 billion patents, papers, and bio-data in real time. Additionally, the company has developed a large language model (LLM) specialized in the biotech field, capable of accurately predicting the commercialization success rate of new drug candidates.

i-Divine's AI technology can select drug candidates with the highest potential for successful clinical trials, offering strategic guidance to minimize the chances of failure in drug development.

Notably, the company has already analyzed the clinical success probabilities of over 16,000 drug candidates worldwide, which found that GI Innovation’s GI-101A and GI-102 have one of the highest probabilities of successful Phase 1 and 2 clinical trials.

“The global AI-driven drug development market is expected to surge to 28 trillion won by 2030,” ​GI Innovation Chairman & CEO Rhee Byung-gun said. “This is a critical area, with long-term R&D projects being promoted at the government level.”

The company expects significant synergy from its AI collaboration with i-Divine, helping it to stay ahead in the rapidly changing drug development landscape, Rhee added.

i-Divine CEO Kim Song-mi also said, “The convergence of AI and biotechnology can bring about groundbreaking changes in drug development.”

This collaboration will not only play a key role in improving the success rate of new drug development but also provide new treatment options to more patients, Kim added.